Parkinson’s Disease (PD) is a complex neurodegenerative disease that affects the quality of life of millions of patients worldwide. In recent years, as medical research continues to deepen, the emergence of a new drug, Xadago…
Pretomanid 200 mg tablets are a novel nitroimidazooxazine-based anti-tuberculosis drug that kills Mycobacterium tuberculosis by inhibiting mycobacterial cell wall synthesis. Its unique dual mechanism of action makes it an excellent candidate for drug-resistant TB. Based…
Introduction Izervay (Avacincaptad Pegol) is a groundbreaking treatment approved for geographic atrophy (GA), an advanced stage of age-related macular degeneration (AMD). GA is a leading cause of vision loss in older adults, with no prior…
Jazz Pharmaceuticals recently announced that its anticancer drug Zepzelca (Lurbinectedin Injection) in combination with Atezolizumab (Tecentriq) achieved significant overall survival (OS) and progression-free survival (PFS) improvements in the first-line maintenance treatment of extensive-stage small cell…
Japanese pharmaceutical company Fuji Yakuhin Co., Ltd. announced that Urece Tablet (Dotinurad Tablet), a novel uric acid-lowering drug developed by the company, has been approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and is…
Leqembi was recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in November 2024 for the treatment of early-stage Alzheimer’s disease, targeting patients with mild cognitive impairment…
Sodium phenylbutyrate is a salt derivative of 4-phenylbutyrate (4-PBA), an aromatic fatty acid with unique metabolic properties. It plays a crucial role in the treatment of urea cycle disorders (UCDs) by facilitating an alternative pathway…
Guangzhou, China, October 15, 2023 – Ivonescimab Akeso (Kangfang Bio, HKEX: 9926.HK) today announced the latest clinical trial of its self-developed bispecific antibody drug Ivonescimab(R&D code: AK112). The drug has demonstrated significant anti-tumor activity in…
In October 2022, the U.S. Food and Drug Administration (FDA) granted accelerated TECVAYLI™ (teclistamab-cqyv) FDA approval, a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. For the treatment of adult patients with relapsed or refractory…
What is Sulbactam-Durlobactam? Sulbactam Durlobactam is a new and special drug combination used to combat multidrug-resistant infections, particularly those caused by Acinetobacter baumannii-calcoaceticus complex, a serious and often difficult-to-treat pathogen. This combination of Sulbactam and…
About Vonvendi Vonvendi (vonicog alfa) is a recombinant von Willebrand factor (VWF) developed by Baxalta. It helps control bleeding episodes by replacing or supplementing the missing or dysfunctional VWF in patients, thereby improving their quality…
On October 15, 2023, the U.S. Food and Drug Administration (FDA) officially approved Enlonstobart Injection (development code: ENL-001) for the treatment of a rare genetic disorder, Idiopathic Fibrotic Syndrome (IFS). This groundbreaking therapy marks another…
